Most liquid biopsies focus on ctDNA—broken fragments of tumor DNA that are highly unstable and difficult to detect in early stages. OncoRevive focuses on Circulating Tumor Cells (CTCs).
CTCs are intact, living cells that shed from the primary tumor into the bloodstream. Because they are whole cells, they carry a wealth of biological information—including proteins, RNA, and intact DNA—that fragments simply cannot provide.
The challenge with CTCs is that they are incredibly rare—often just one cell among billions of healthy blood cells. OncoRevive solves this through our proprietary nanotechnology platform.
High-Efficiency Isolation: Our nanoparticles act like molecular magnets, allowing us to isolate these rare cells with unprecedented speed and purity, far surpassing traditional enrichment methods.
Targeted Tagging: We utilize engineered nanoparticles designed to recognize and "tag" specific biomarkers on the surface and inside of CTCs.
Detecting biomarkers at the earliest stages of cancer requires extraordinary sensitivity. By combining our nanoparticle tagging with advanced spectroscopy techniques, we achieve a breakthrough in signal detection:
The Power of Spectroscopy: Our approach amplifies the optical signal of cancer biomarkers by up to 1 billion times.
Multiplexing Capabilities: Unlike traditional tests that look for one marker at a time, our technology can analyze multiple biomarkers simultaneously. This "multiplex" view provides a comprehensive molecular fingerprint of the tumor, increasing diagnostic accuracy.
We have replaced complex, multi-day genomic sequencing with a fast and simple workflow.
Rapid Turnaround: Our spectroscopy-based analysis delivers results in a fraction of the time (2 hours) required by Next-Generation Sequencing (NGS) (2 weeks).
Point-of-Care Ready: By reducing the complexity of the laboratory process, we are making high-end cancer monitoring accessible to local clinics, not just specialized central labs.
